Navigation Links
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Date:7/1/2008

As previously announced, the Company is evaluating the Company's research and development programs, including related assets and costs, and strategic alternatives available to the Company.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including the Company's belief that the data from the L-MTP-PE Phase 3 study warrants regulatory approval in Europe and the United States, the Company's plans to address the remaining questions with respect to the MAA for L-MTP-PE during the clock-stop granted by the CHMP, including the Company's plans for completion of data analysis and submission of responses to the CHMP, the Company's expectation that it will attend an oral explanation hearing at the CHMP's September plenary meeting, the expected timing of receipt of a final opinion from the CHMP and receipt of a final regulatory decision regarding the MAA in the European Union, as well as the Company's plans to collect, analyze and submit additional Phase 3 data in an amended NDA for L-MTP-PE, including the expected timing for such amended NDA, and to respond to other matters raised by the FDA and the Company's plans to evaluate strategic alternatives. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, whether the European Commission will follow the final opinion of the CHMP, whether the timing for the final opinion of the CHMP and the regulatory decision in Europe will occur as expected by the Company, the possibility that additional data from the Phase 3 clinical trial of L-MTP-PE and other information in any amendment to the NDA for L-MTP-PE submitted by the Company may not provide adequate support for regulatory approval of L-MTP-PE
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Isis Pharmaceuticals Conference Call Notice
2. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
3. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
4. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
5. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
6. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
7. Pharmasset Receives Notice of Allowance
8. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
9. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... Oct. 20, 2014 CTI BioPharma Corp. (CTI) ... report its third quarter 2014 financial results on Wednesday, ... financial markets. Following the announcement, members of the management ... the results and provide a general corporate update at ... event can be obtained as follows: Wednesday, ...
(Date:10/19/2014)... 2014 Große Pharmafirmen werden ... Problem dabei ist, dass große Pharmafirmen nicht willens ... teilen. Es war deshalb nicht einfach, ... umso mehr, dass es uns gelungen ist! Wir ... aufzuschreiben - mit einem Vorbehalt - einige haben ...
(Date:10/17/2014)... CHAPEL HILL, N.C. , Oct. 17, 2014 ... healthcare landscape, the Medical Affairs function has come ... metrics, allocating resources efficiently and managing globalization.  ... at Best Practices, LLC is dedicated to providing ... issues. The Medical Affairs Consortium is a service ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... Calif., Feb. 8, 2011 Anthera Pharmaceuticals, Inc. (Nasdaq: ... to treat serious diseases associated with abnormal auto-immune responses ... Rosania to the position of Vice President of Global ... for developing global regulatory strategies and managing all aspects ...
... 2011 Genomic Health, Inc. (Nasdaq: GHDX ) ... ended December 31, 2010. Total revenue for the ... with $149.5 million in 2009, an increase of 19 percent. ... 31, 2010, compared with $146.6 million in 2009.  Contract revenue ...
Cached Medicine Technology:Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance 2Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance 3Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 2Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 3Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 4Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 5Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 6Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 7Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 8Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 9
(Date:10/20/2014)... 20, 2014 Succeed is proud to announce ... who participated in the Every Body Walk! campaign ... awareness project that encourages workers to be more active outside ... Program, which concluded at the end of September, was a ... and metro areas. Participating companies gave their staff pedometers ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 National Teen ... Chapter of the American Academy of Pediatrics (Ohio AAP, ... (NHTSA) in encouraging parents of teen drivers to talk to ... the road. , Motor vehicle crashes are the leading cause ... teen drivers involved in fatal crashes, and 859 (42%) of ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center for ... ROI on membership dues at 12.5. In other words, for ... value to member hospitals. The calculation used to determine member ... , “This is the first time we’ve actually been able ... is really sound,” said Bill Ryan , president and ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... to be introduced in the U.S., has a lot to ... time when our country recognizes the achievements and contributions of ... marks the anniversary for Punzoné, and today it shares its ... and take a trip to Italy - even if it ...
(Date:10/20/2014)... Maryland, USA (PRWEB) October 20, 2014 ... to track interventions? Here comes a wonderful app Metassessor ... mobile app development company helped its client “Intervention ... more efficiently. The app is designed for iOS 4.3 ... iPod touch. This app is optimized for iPhone 5. ...
Breaking Medicine News(10 mins):Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... gain is an early symptom, not a direct cause , , ... it causes, is the actual cause of metabolic syndrome, suggests ... Texas Southwestern Medical Center at Dallas. , Metabolic syndrome ... of developing insulin resistance, fatty liver, heart disease and type ...
... YORK, April 18 Soy foods have staying power,according to ... in,the U.S. The soy food and beverage market topped $2 ... bar and soymilk products. Sales of soy,foods and beverages grew ... that the market will continue to increase at a healthy ...
... 18 BlueCross BlueShield of South,Carolina today announced that ... of directors., A native of Elberton, Ga., Shaw ... of Micco Corp., a family investment corporation.,She previously worked ... & S National,Bank of South Carolina, and Manly Investment ...
... 3 September 2008 the 21st Congress of ... held in Barcelona, Spain.,This Congress is the largest ... of a high scientific standard, attended by more than ... neurologists, psychologists and neuroscience researchers) from all over the ...
... to reduce air trapped in the lungs during exercise, ... A computer program may help people with chronic obstructive ... and breathe more efficiently, according to U.S. researchers who ... double-edged sword: The incapacitating lung condition can cause such ...
... is First in Centers for Comprehensive Women,s Care ... BlueShield of,Tennessee has designated Baptist Memorial Hospital for ... Comprehensive Women,s Care (CCWC) program., The CCWC ... and newborns, health care with a focus on ...
Cached Medicine News:Health News:Metabolic Syndrome Triggered by Overeating, Not Obesity 2Health News:Soy Foods Beat Out Fresh Fish and Meat for 'Best New Products Tried By Consumers' While Demand and Profits Continue to Grow 2Health News:Shaw Elected to S.C. BlueCross BlueShield Board 2Health News:21st Congress of the College of Neuropsychopharmacology 2Health News:Computer Program Helps COPD Patients Monitor Breathing 2Health News:BlueCross Recognizes Baptist Women's Hospital 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: